| Status | Acronym | ISRCTN | EudraCT | NCT (clinicaltrials.gov) | DRKS |
|---|---|---|---|---|---|
| Active |
A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients
Purpose / Objectives
Primary Outcome
Protocol according to the master protocol “A Multi-center, Adaptive, Randomized Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for the Treatment of COVID-19 in Hospitalized Patients”
Based on the recently published WHO master protocol, the BIH Clinical Study Center (BIH CSC) has developed a central COVID-19 master protocol to harmonize and speed up initiation of COVID-19 clinical trials. The master protocol is available from CSC or via covid19-researchboard@charite.de .
Diagnosis
- COVID-19 (SARS-CoV-2 Infection)
Depending individual clinical trial
Target population
Inclusion criteria
Depending on individual clinical trial
Exclusion criteria
Depending on individual clinical trial
Documents (password protected)
Go to download area (no documents yet)